GlassScriptPhysician profile
Kevin James Kuisel
NPI 1770064461
$2,333.46
in general payments reported to CMS, 2019-2025
9 companies · $582 in 2025
The $582 reported for 2025 was more than what 79% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,185 · 2024: $566 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,287 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,286.55 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $627.56 | 2023-2024 | Auvelity |
| Alkermes, INC. | $430.36 | 2023-2024 | Lybalvi, Vivitrol, Aristada |
| Abbvie INC. | $367.52 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $338.76 | 2023-2025 | Caplyta |
| Braeburn INC. | $229.13 | 2023-2025 | Brixadi |
| Indivior INC. | $206.14 | 2023-2025 | Sublocade |
| Lundbeck LLC | $75.16 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $45.59 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $13.24 | 2024 | Uzedy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Kuisel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.